A5084350074- Hepatocellular Carcinoma Treatment and Prognosis
- Urinary Bladder and Prostate Research
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Prostate Cancer Diagnosis and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Urological Disorders and Treatments
- Hepatitis B Virus Studies
- Cerebrovascular and Carotid Artery Diseases
- Ferroptosis and cancer prognosis
- Aortic aneurysm repair treatments
- Pancreatic and Hepatic Oncology Research
- Moyamoya disease diagnosis and treatment
- Hepatitis C virus research
- Renal cell carcinoma treatment
- Atomic and Subatomic Physics Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Stress, Anesthesia, and Immune Response
- Anesthesia and Sedative Agents
- Genetic and Kidney Cyst Diseases
- Urologic and reproductive health conditions
- Cancer, Hypoxia, and Metabolism
Nanjing Medical University
2019-2025
Jiangsu Cancer Hospital
2023-2025
Jiangsu Province Hospital
2019-2021
Huashan Hospital
2017
Fudan University
2017
Capital Medical University
2012
Abstract Background and Aim The study aims to investigate the efficacy safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib immune checkpoint inhibitors (ICIs) versus ICIs for hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) refractoriness. Methods Patients intermediate or advanced TACE‐refractory HCC who received without HAIC between 2020 2022 were retrospectively reviewed. tumor response, overall survival (OS), progression‐free (PFS),...
The combination of regorafenib and immune checkpoint inhibitor (ICI) has been the most popular second-line systemic therapy for advanced hepatocellular carcinoma (HCC). However, considering good anti-tumor performance lenvatinib, combined immunotherapy on basis lenvatinib after first-line failure is also in clinical practice. This study aimed to compare efficacy safety plus ICI (TACE-R-I) versus (TACE-L-I) patients with HCC failure. In this single-center retrospective study, 164 were...
Nontraumatic spontaneous subarachnoid hemorrhage (SAH) is associated with a high mortality. This study was conducted to investigate the epidemiological features of nontraumatic SAH in China.From January 2006 December 2008, clinical data patients from 32 major neurosurgical centers China were evaluated. Emergent digital subtraction angiography (DSA) performed for diagnosis sources acute stage (≤3 days). The results and complications emergent DSA analyzed. Repeated or computed tomography (CTA)...
The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed identify a biomarker for predicting TACE in HCC patients and investigate its correlations the tumor microenvironment pre-TACE radiomics features.
<title>Abstract</title> <bold>Background: </bold>The lenvatinib combined with immunotherapy therapies as first-line treatment are still controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of monotherapy (L) synchronous therapy (LI) sequential (L-LI) uHCC patients. <bold>Methods:</bold>181 patients were enrolled this study. Patients classified into three groups: (1) Lenvatinib (L). (2) Synchronous (lenvatinib plus immune...
Purpose: In the present study, we aimed to assess effectiveness and safety of immune-targeted therapy (IT) with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) portal vein tumor thrombosis (PVTT). Patients methods: This was a multicenter retrospective study that included 265 HCC patients PVTT (IT + TACE: 82, IT: 183). Overall survival (OS) progression-free (PFS), as well responses adverse events, were evaluated. Results: in IT TACE group...
<title>Abstract</title> <bold>Purpose:</bold>To demonstrate the potential benefits of additional transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) after failure first-line systemic treatment (ST).<bold>Methods</bold>: This retrospective single-center study was conducted between January 2020 and December 2022 on patients with HCC who failed to respond initial ST. Patients had previously undergone TACE were excluded. Eligible underwent on-demand in addition ST...
Abstract Introduction: The Lenvatinib combined with immunotherapy therapies are still controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of monotherapy (L) combination therapy plus immune checkpoint inhibitors (ICIs) administered synchronously (LI) sequential initial followed by subsequent addition ICIs (L-LI) uHCC patients. Methods 181 patients were enrolled this study. Patients classified into three groups: (1) (L). (2)...